NCT00325117View on ClinicalTrials.gov

To Assess the Efficacy and Safety of Vildagliptin as Add-on Therapy to Sulfonylurea in Patients With Type 2 Diabetes Inadequately Controlled With Sulfonylurea Monotherapy

PHASE3CompletedINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

April 30, 2006

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Vildagliptin

Trial Locations (1)

Unknown

Novartis Pharmaceuticals, Tokyo

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Novartis

INDUSTRY

NCT00325117 - To Assess the Efficacy and Safety of Vildagliptin as Add-on Therapy to Sulfonylurea in Patients With Type 2 Diabetes Inadequately Controlled With Sulfonylurea Monotherapy | Biotech Hunter | Biotech Hunter